RxDoctor Payments Data

Sol de Jesus, MD

Neurology · Hershey, PANPI 1306149851

Payments from drug & device makers

$122,577in general payments, 2019–2025

Across 271 payments — averaging $452.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$118K
  • Boston Scientific$4K
  • Neurocrine Biosciences, Inc.$366
  • Acadia Pharmaceuticals Inc$225
  • Abbott$224
  • Amneal Pharmaceuticals LLC$109
  • plus $288 from 4 others

What the payments were for

  • Consulting fees$11,1879%
  • Speaking & faculty fees$87,26471%
  • Travel & lodging$16,01213%
  • Food & beverage$8,1147%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$122,577 in reported general payments places this provider in the 85th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$18,328
Medicare patients
131
Services billed
225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate13$120,773
RytaryCarbidopa/Levodopa49$60,960
NourianzIstradefylline12$25,484
Carbidopa-LevodopaCarbidopa/Levodopa195$10,772
Entacapone20$7,889
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone22$6,315
Selegiline Hcl20$4,786
Carbidopa-Levodopa ErCarbidopa/Levodopa86$3,767
Rasagiline Mesylate34$3,320
AmantadineAmantadine Hcl55$1,612
Primidone38$962
Ropinirole ErRopinirole Hcl14$714
Donepezil Hcl38$566
Gabapentin43$523
Clonazepam57$490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$225$120,77313 claims
Amneal Pharmaceuticals LLCRytary$109$60,96049 claims
Kyowa Kirin, Inc.Nourianz$77$25,48412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Hershey

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →